China Pediatric Pharmaceuticals has completed a reverse merger, taking over the company formerly known as Lid Hair Studios International. China Pediatric Pharma, which is headquartered in Xi’an, produces and distributes prescription and OTC drugs for children, some of which are western and the rest based on TCM. The company reported $7.1 million in revenue for the six months of 2009 and $1.6 million in net income. The net income is equivalent to 19 cents per share. More details...

Stock Symbol: (OTCBB: LHSI)

California's stem cell institute has signed an MOU with China's Ministry of Science and Technology, though details will not be released until next week; ChinaSF, the San Francisco agency in charge of outreach to China businesses, signed a MOU with China Medical City of Taizhou; China Pediatric Pharmaceuticals completed a reverse merger; Starr International agreed to invest $20.5 million in Techpool Bio-Pharma Company; Tongjitang Chinese Medicines announced a 19.3 million share buyback; Merial broke ground on a $70 million expansion of its Nanchang Park manufacturing facility; Servier is collaborating with the Shanghai Institute of Materia Medica on new cancer therapies; China investigators have shown bioluminescence imaging (BLI) can be used to monitor tumors in the eye; Celsion received SFDA approval to include China sites a clinical trial of a new liver cancer therapy; and finally, Biostar Pharma was awarded a China patent for a new TCM treatment for hepatitis B. More details...

Stock Symbols: (OTCBB: LHSI) (NYSE: TCM) (NSDQ: CLSN) (OTCBB: BSPM)